Printer Friendly
The Free Library
14,506,104 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Griffin Securities Initiates Research Coverage of CytRx Corporation with Buy Rating; Analyst Sets 12-month Target Price of $4.00.


NEW YORK -- Griffin Securities initiated research coverage of CytRx Corporation (NasdaqSC:CYTR) with a buy rating and a 12-month price target of $4.00. Chrystyna Bedrij, Director of Research, issued the report.

Griffin Securities, Inc., is a New York City based Investment Banking firm providing Corporate Finance, Merger & Acquisitions, Asset Management, Brokerage and Research services for Institutional, Corporate and Private Clients. The firm is a member of the National Association of Securities Dealers National Association of Securities Dealers (NASD)

Nonprofit organization formed under the joint sponsorship of the investment bankers' conference and the SEC to comply with the Maloney Act, which provides for the regulation of the OTC market.
 (NASD NASD

See: National Association of Securities Dealers


NASD

See National Association of Securities Dealers (NASD).
) (Broker ID 43229) and the Securities Investor Protection Corporation Securities Investor Protection Corporation (SIPC)

A nonprofit corporation that insures customers' securities and cash held by member brokerage firms against the failure of those firms.
 (SIPC (Simply Interactive PC) An earlier umbrella term from Microsoft and Intel for a PC that works like a home appliance. For example, it has a sealed case, uses external connectors for expansion and boots in just a couple of seconds. ). The group provides financial advisory services to emerging growth companies, institutions, and high net worth individuals.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Dec 19, 2005
Words:100
Previous Article:Videotron Selects Nuera Media Gateways for Cable Telephone Expansion.
Next Article:Breaking News: Human BioSystems Confirms Earlier Organ Preservation Survival Test Results-Now Seeks Strategic Partner.
Topics:



Related Articles
Public Analysis & Review Announces Investment Opinion on Vasogen Inc.
Taglich Brothers Initiates Coverage of CytRx Corporation.
Griffin Securities Initiates Research Coverage of CytRx Corporation With Buy Rating; Analyst Sets 12-month Target Price of $5.23.
Griffin Securities Increases Its 12-Month Price Target to $7.00 on CytRx Corporation.
Rodman & Renshaw, LLC Announces Investment Opinion on Cephalon, Inc.
Dutton Associates Announces Investment Opinion: Nymox Pharmaceutical Strong Speculative Buy Rating In Initiating Coverage By Dutton Associates.
Biotech success could lead to CytRx payoff, but there's risk.(Company Profile)
Dutton Associates Announces Investment Opinion: Nymox Pharmaceutical Strong Speculative Buy Rating in Update Coverage by Dutton Associates.
Rodman & Renshaw, LLC Announces Investment Opinion: Rodman & Renshaw, LLC Initiates Coverage of Cytogen Corporation With A Market Outperform Rating.
Rodman & Renshaw, LLC Initiates Coverage of Cell Therapeutics, Inc. With A Market Outperform Rating.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles